Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
The cash consideration for the above acquisition will be Euro 26 million.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
Targeted action improves quality of healing of tendon and suspensory ligament injuries in horses
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
